This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieTeaching Note HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Starting at €0.00
-
Eddie Bauer, Inc. (Spanish Version)
Bell, David E.; Leamon, AnnCase HBS-503S35MarketingEddie Bauer ha decidido coordinar su estrategia de comercialización (precio, la selección) a través de sus tiendas y catálogo. Pero con el comercio electrónico, es sensato esto todavía?Starting at €8.20
-
Compaq Computer: grupos de enfoque
Bell, David E.; Leamon, AnnCase HBS-514S09MarketingDa el informe final, ambos resultados y la metodología, del grupo de enfoque en la nueva portátil de consumo de Compaq Computer. Se describen los grupos, método de selección, y la metodología en detalle. En caso de Compaq basar su diseño de producto en las opiniones de 64 personas? Se debe utilizar con el video.Starting at €8.20
-
Computadoras Compaq: Intel Inside
Bell, David E.; Leamon, AnnCase HBS-503S44MarketingPresenta los resultados de la investigación cuantitativa y cualitativa de mercado sobre la posible aceptación de un procesador Intel no en la línea de portátiles de consumo de Compaq Computer. Si el portátil no es de Intel de bajo costo, es un éxito, la empresa va a mantener o aumentar su participación del 45% del mercado. Si no es así, podría dejar de ser un jugador en el mercado que ha creado y llenado. Los estudiantes deben evaluar la fiabilid...Starting at €8.20
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
The Millennium Challenge Corporation and Ghana
Ebrahim, Alnoor; Rangan, V. KasturiCase HBS-310025-EA U.S. government agency, the Millennium Challenge Corporation (MCC), provides aid to developing countries, focusing on poverty reduction through economic growth. It measures results through an economic rate of return based on increases in farmer incomes anticipated over twenty years. As MCC and Ghana finalize a $547 million grant for agriculture and transportation infrastructure, they come up against an accountability and measurement problem: ho...Starting at €8.20
-
Microsoft's IP Ventures
Lerner, Josh; Leamon, AnnCase HBS-810096-EEntrepreneurshipMicrosoft's IP Ventures program, through which Microsoft spun out promising but unused technologies into new companies, is a new approach to corporate venture capital. The program provides "IP for equity" and has proven very successful in achieving its main goals-improved morale among researchers who like knowing their technology is being used, improved relationships with the venture capital community particularly in Silicon Valley, and good PR. ...Starting at €8.20
-
Bridges Ventures
Rangan, V. Kasturi; Appleby, SarahCase HBS-514001-EMarketingTo maximize their effectiveness, color cases should be printed in color. Bridges Ventures, a UK-based impact investor with double-digit returns on its investments, is reflecting on its social impact and pondering its future course.Starting at €8.20
-
Communities In Schools (Atlanta): Innovating a College Program
Rangan, V. Kasturi; Applegate, Lynda M.; Lefort, AlexisCase HBS-823070-EEntrepreneurshipFrank Brown, CIS of Atlanta's new Black CEO, was keen to extend CIS's well-honed case management in schools program to youth in college. Founded 50 years ago by Bill Milliken, CIS, a network of 110 affiliates, had built a strong program of assisting and supporting youth in poverty schools to complete their high school education. CIS Atlanta's thrust which would be a new stretch for the network had the strong backing of the network's new national ...Starting at €8.20